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Abstract  
Introduction: Metastasis to the breast from non-mammary malignancy is rare, with a reported incidence of 
less than 1%[2-4]. Aside from hematologic malignancies and contralateral breast cancer, the most common 
primary malignancies that metastasize to the breast are lung, ovarian, gastrointestinal cancers, and melanoma.  
Presentation of Case: We present an 82-year-old female with metastatic breast cancer arising from a primary 
papillary thyroid carcinoma. She presented with a palpable right breast mass 4 years after resection and 
treatment of a primary thyroid cancer.  
Conclusion: Ultrasound guided core biopsy and immunohistochemical staining demonstrated metastatic 
papillary thyroid carcinoma. The patient underwent lymphoscintigraphy and subsequent resection of the 
breast mass along with two axillary lymph nodes.  
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Introduction 
The lifetime risk of breast cancer is 12.3 percent[1]. Metastatic neoplasms to the breast and surrounding 
tissue are exceptionally rare and account for approximately 2% of all mammary malignancies. The most 
common metastasis to the breast are from a contralateral breast cancer.  Non-mammary breast metastasis 
account for less than 1% of breast neoplasms[2-4]. In spite of its rarity, prompt and accurate diagnosis of 
non-mammary metastatic breast malignancy is essential in avoiding improper treatment, which may 
improve patient outcomes while minimizing adverse effects and complications[5, 6]. 
Thyroid papillary carcinoma is the most common malignancy of the thyroid and, without distant 
metastasis, carries a good prognosis with a mortality rate of 6%. Distant metastasis is uncommon and 
usually represents a more aggressive neoplasm with a worse prognosis[7-9]. TPC commonly metastasizes 
to local lymph nodes, the lungs and bone. A review of literature have demonstrated few cases of TPC 
metastasizing the breast[10, 11].  
Case Presentation 
An 82-year-old, African-American, non-smoker female presented to the outpatient medical clinic with 
complaints of a large right breast mass of a couple months duration with a recent increase in size over the 
past couple of weeks. She had a documented history of a 7cm poorly-differentiated thyroid carcinoma 
with invasion of surrounding muscle and vasculature in 2008, for which she underwent a subtotal 
thyroidectomy, followed by radioactive iodine treatment. Two years later, the patient was found via ultra 
sound to have two localized lesions of 3.3 and 2.5 cm in the midline of neck and left thyroid respectively. 
Biopsy confirmed recurrent poorly differentiated thyroid carcinoma and the masses were subsequently 
resected. In 2012, a chest computed tomography scan (CT), followed by a whole body positron emission 
tomography scan (PET/CT) revealed the presence of multiple ‘hot’ pulmonary nodules with a dominant 
6mm nodule in the left upper lobe. Based on size and lack of symptoms, pulmonary lesions would be left 
to observation(Figure 1a, 1b).  
 
  
Figure 1a and 1b:  CT chest:  Axial sections (lung windows) showing multiple bilateral lung nodules, suspicious 
for metastases. 
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At presentation in our clinic, physical examination revealed a large, relatively hard right breast lump, 
palpable infero-laterally with respect to the nipple, and measuring approximately 6cm vertical and 7cm 
horizontal. There was no nipple retraction or discharge. Diagnostic ultrasound showed an irregular, 
hypoechoic mass with heterogenous echotexture at eight o’clock,5cm from the nipple, measuring 4.5 x 
3.5 x 4.4cm (Figure 2a, 2b). Targeted ultrasound of the right axilla demonstrated a normal appearing 
lymph node. The patient underwent an ultrasound guided core biopsy of the mass leaving a marking clip 
in place. Post biopsy mammography showed the mass along with biopsy clip (Figure 3a, 3b). 
Immunohistochemical (IHC) staining performed on the specimens were strongly positive for 
thyroglobulin, CK7, PAX8, vimentin and TTF-1. Cells were negative for CK20, S100, CDX2 and 
GATA3. Tumor cells were weakly positive for estrogen and progesterone receptor and negative for 
Her-2/neu; proliferation rate by Ki-67 was low (10%). IHC findings were consistent with metastatic 
papillary thyroid carcinoma.  
Sentinel lymphoscintigraphy with 0.55 mCi technetium-99m demonstrated two small foci of uptake in 
the right axilla.  The patient underwent a right partial mastectomy of the mass and right axillary lymph 
node dissection. Pathology of the mass was consistent with a primary thyroid carcinoma. Lymph nodes 
were negative for metastatic disease. The patient tolerated the procedure well without complication and 
was urged to follow up with her oncologist for post-operative treatment options. 
 
 
  
Figure 2a and 2b:  Right breast ultrasound showing a hypoechoic mass with circumscribed margins at the 8:00 5 
cm from nipple, corresponding to the mass seen on the mammogram. 
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Figure 3a and Fig 3b:  Right diagnostic mammogram performed after the ultrasound guided biopsy of the breast 
mass showing the round mass at the 8:00 location containing a biopsy clip. 
Discussion 
Papillary thyroid carcinoma (PTC) is a well differentiated neoplasm characterized by an indolent growth 
pattern with low metastatic potential and a relatively good prognosis. Usually localized to the thyroid, 
PTC, responds well to total thyroidectomy, radioiodine-131 ablation and hormone suppression measures 
and carries a mortality approaching 6 percent[7, 9]. Metastasis, conversely, drastically reduces survival 
rate and overall prognosis. The most common involvement being of regional lymph nodes, lung and bone. 
Distant metastasis to organs inclusive of brain, breast, liver, kidney and other are relatively rare, 
increasing the risk of being overlooked or misdiagnosed in the clinical setting[10, 11]. An increased 
morality results from age over 45, multiple organ involvement, soft-tissue invasion of primary tumor, all 
existing in the present case[7, 8, 12]. Proper diagnosis allows for more effective treatment planning and 
prognosis[5, 6].  
Non-mammary metastasis to the breast is uncommon with a rate of 0.4-2 percent of breast 
malignancies. It is even rarer for a breast malignancy to be metastasis from thyroid cancer with few more 
than 11 cases documented in recent literature. The median time between primary malignancy diagnosis 
and breast metastasis is about 2 years, with a median survival after diagnosis in the range of 10-15 
months[6, 14].  Most reports of metastatic disease to the breast have been documented through 
independent institution reviews, case reports or meta-analyses of obtainable studies. Williams and 
colleagues at University of Texas M.D. Anderson Cancer Center confirmed 169 patients with metastatic 
disease to the breast from over a 15 year period; of these cases, 5.3% originated from the head &neck 
with no distinction of PTC[6]. Later, DeLair and colleagues reported 85 cases over a 20 year period from 
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Memorial Sloan-Kettering Cancer Center. Data from this study demonstrated that 2.5% of cases arose 
from PTC [2]. More recently, Zhou et al. identified 28 similar cases, none of which demonstrated 
metastatic PTC [15]. These studies all noted an increased incidence with a previous primary diagnosis, 
advanced stage of disease, and age over 45years, but with an unpredictable occurrence of PTC.  
The differentiation between primary breast cancer and metastatic cancer to the breast through imaging 
is challenging. A metastatic lesion could mimic a primary breast tumor. PTC in addition to other 
metastatic malignancies to the breast, usually present as multiple well-circumscribed masses on a 
mammogram and ultrasound, with potential lymph node involvement in patients with an advanced 
disease state. Metastatic tumors to the breast are more likely to present bilaterally, with multiple areas of 
involvement. Non-mammary metastatic involvement of the breast usually does not show calcifications on 
mammogram[4, 5, 15].  
Apart from identifying the solid nature of a mass, ultrasound also assists in biopsy guidance as seen in 
our patient. However, it is not possible to make a definitive diagnosis of metastasis based solely on 
imaging findings[16].As demonstrated in our case, immunohistochemistry played a vital role in 
confirming the primary tumor, in addition to ruling out a breast component. Cytokeratins are effective 
markers for epithelial differentiation and are highly expressed in tumors of carcinomatous nature[5, 17]. 
Our specimen stained positive for CK7, which is expressed in 98% and 96% of all thyroid and breast 
tumors respectively. CK20 stained negative which has a 0% expression in both origins. Following an 
algorithmic approach illustrated by Dabbs (Diagnostic immunohistochemistry, 2013), CK7+/CK20- our 
specimen stained positive for TTF-1, a marker for thyroid transcription factor 1, which is positive in all 
thyroid origins as well as 75% of lung carcinomas. Subsequently, thyroid origin was confirmed by 
staining positive for both thyroglobulin, a glycoprotein positive in all thyroid excluding anaplastic, and 
PAX-8, a paired box gene required for development of the thyroid. Vimentin stained positive, which is 
expressed in >50% of thyroid carcinoma, and <10% of breast ductal-lobular carcinoma[17].  
Specimens stained negative for S-100, ruling out most carcinomas and melanoma, while a negative 
CDX2 and GATA3 dismissed intestinal and mammary gland origin respectively. Cells staining weakly 
positive for estrogen and progesterone as well as a negative stain for Her-2/Neu confirmed the exclusion 
of breast as the origin of this lesion. Low proliferation of nuclear protein Ki-67 contributed to the 
exclusion of breast derivation[17].  
Conclusion 
In conclusion, we report a rare case of metastatic involvement of the breast by a primary papillary thyroid 
carcinoma. Generally, metastatic tumors to the breast are associated with a poor prognosis with a median 
survival time of ten months from the time of diagnosis. It is important to consider metastatic disease in 
the differential diagnosis of breast masses, as the management may differ greatly. A thorough radiological 
examination, cytological and immunohistochemical analysis, in addition to clinical correlation provides 
the best opportunity to make an accurate diagnosis.  
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